According to the West German Study Group PlanB trial, six cycles of TC was non-inferior to four cycles of epirubicin/cyclophosphamide, followed by four cycles of docetaxel (EC-T) in patients with HER2 negative early breast cancer with pN0 high genomic risk that included hormone receptor-negative patients or pN1 with genomic intermediate to high-risk disease. This evidence concerns the gene ERBB2 and breast carcinoma.